SNX-5422 (mesylate)

SNX-5422 Mesylate (PF-04929113 Mesylate), a prodrug of SNX-2112, is an orally active Hsp90 inhibitor, with a Kd of 41 nM, and also induces Her-2 degradation, with an IC50 of 37 nM.

Product Specifications

CAS Number

[1173111-67-5]

Product Name Alternative

PF-04929113 (mesylate)

UNSPSC

12352005

Hazard Statement

H302-H315-H319-H335

Target

HSP

Type

Reference compound

Related Pathways

Cell Cycle/DNA Damage; Metabolic Enzyme/Protease

Applications

Cancer-programmed cell death

Field of Research

Cancer

Assay Protocol

https://www.medchemexpress.com/PF-04929113-Mesylate.html

Solubility

10 mM in DMSO

Smiles

CS(=O)(O)=O.O=C1CC(C)(C)CC2=C1C(C(F)(F)F)=NN2C3=CC=C(C(N[C@@H]4CC[C@@H](OC(CN)=O)CC4)=C3)C(N)=O

Molecular Formula

C26H34F3N5O7S

Molecular Weight

617.64

Precautions

P261-P264-P270-P271-P280-P302+P352-P304+P340-P305+P351+P338-P330-P362+P364-P403+P233-P405-P501

References & Citations

[3]Kim SH, et al. The heat shock protein 90 inhibitor SNX5422 has a synergistic activity with histone deacetylase inhibitors in induction of death of anaplastic thyroid carcinoma cells. Endocrine. 2016 Feb;51 (2) :274-82.|[1]Huang KH, et al. Discovery of novel 2-aminobenzamide inhibitors of heat shock protein 90 as potent, selective and orally active antitumor agents. J Med Chem. 2009 Jul 23;52 (14) :4288-305|[2]Chandarlapaty S, et al. SNX2112, a synthetic heat shock protein 90 inhibitor, has potent antitumor activity against HER kinase-dependent cancers. Clin Cancer Res. 2008 Jan 1;14 (1) :240-8.